Blood Cancer Information

In this section you will find disease specific information on the main types of blood cancers and allied blood disorders.

Leukaemia

Leukaemia is a cancer which starts in blood-forming tissue, usually the bone marrow. It leads to the over-production of abnormal white blood cells, the part of the immune system which defends the body against infection.

Signs and symptoms of leukaemia

Leukaemia can be hard to spot because the signs and symptoms are common to other unrelated illnesses. Knowing what to look out for could help you make the decision to visit your GP sooner for a blood test.

Leukaemia Myths

There are many myths about leukaemia. Get yourself clued up with the following guide

Lymphoma

Lymphoma is cancer that starts in the lymph glands or other organs of the lymphatic system. The lymphatic system is a network of fine vessels, glands and channels which occur throughout the body.

Myeloma

Myeloma, also known as multiple myeloma, is a cancer of the bone marrow which affects the plasma cells, a type of blood cell.

Aplastic Anaemia

Aplastic anaemia (AA) is a rare condition in which the bone marrow fails to produce all three major types of blood cell. It is not a form of cancer.

Myeloproliferative neoplasms (MPN)

Myeloproliferative neoplasms, also known as myeloproliferative disorders (MPDs) are a group of conditions that are closely related to leukaemia.

Myelodysplastic syndromes (MDS)

Myelodysplastic syndromes (MDS) are a group of diseases where the production of blood cells by the bone marrow is disrupted.

Changes to your nails

Some treatments for blood cancer may change the usual look and feel of your nails and can cause discomfort. There are ways to manage this to reduce discomfort and improve the appearance of your nails.

Read More

Take a Moment to Catch Up

View our latest news and blog articles

September 18th

CVs – a how-to guide

In our second blog on getting back to work, we look at CVs, their uses, and how to write one....

September 16th

Blood Cancer Awareness Month so far

We’re halfway through Blood Cancer Awareness Month and our Spot Leukaemia campaign. Here, we round up the campaign so far....

September 7th

The Scottish Medicine Consortium (SMC) approves gilteritinib for relapsed/refractory AML patients in Scotland

The Scottish Medicine Consortium (SMC) has recommended the use of gilteritinib for patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation. Find out what this means for patients in Scotland here....